AIM ImmunoTech (NYSE:AIM – Get Free Report) and Monte Rosa Therapeutics (NASDAQ:GLUE – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, profitability, dividends and earnings. Earnings and Valuation This table compares […]
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE – Free Report) – Research analysts at Wedbush upped their Q2 2024 earnings per share estimates for Monte Rosa Therapeutics in a note issued to investors on Tuesday, May 21st. Wedbush analyst R. Driscoll now forecasts that the company will post earnings of ($0.37) per share for the quarter, up […]
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE – Free Report) – Investment analysts at Wedbush issued their FY2023 earnings estimates for Monte Rosa Therapeutics in a report released on Wednesday, February 14th. Wedbush analyst R. Driscoll forecasts that the company will post earnings of ($2.63) per share for the year. Wedbush currently has a “Outperform” rating and […]
Coeptis Therapeutics (NASDAQ:COEP – Get Free Report) and Monte Rosa Therapeutics (NASDAQ:GLUE – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, profitability, dividends and earnings. Profitability This table compares Coeptis Therapeutics […]
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE – Free Report) – Equities researchers at Leerink Partnrs raised their FY2023 EPS estimates for shares of Monte Rosa Therapeutics in a note issued to investors on Tuesday, October 17th. Leerink Partnrs analyst C. Liu now forecasts that the company will earn ($1.75) per share for the year, up from […]